- Alligator reports that it has submitted a CTA application to the relevant regulatory authorities to start a P-II efficacy study of its CD40 targeting antibody mitazalimab
- Upcoming P-II OPTIMIZE-1 study is assessing mitazalimab + CT (mFolfirinox) in patients with metastatic pancreatic cancer and will be performed at several clinics in Europe involve up to 66 patients. First patient inclusion will be planned during the Q1, 2021 & will determine the best dose for the combination with CT
- Mitazalimab has prior reported positive results from two P-I studies, first performed by Alligator and second by Janssen, demonstrating a manageable safety profile and early signs of efficacy
Click here to read full press release/ article | Ref: Alligator Bioscience | Image: Linkedin
The post Alligator Bioscience Submits CTA for the P-II OPTIMIZE-1 Study of Mitazalimab first appeared on PharmaShots.